Information Provided By:
Fly News Breaks for February 9, 2018
CVS
Feb 9, 2018 | 11:15 EDT
Needham analyst Kevin Caliendo lowered his price target on CVS Health to $98 from $100 after the company's earnings. Caliendo notes that while the PBM and retail businesses were solid, the negative development of CVS planning to reinvest $1.2B of tax reform windfall in compensation and infrastructure "undermined the positives". The analyst is also concerned with President Trump's budget proposal focusing on curbing drug prices. However, he maintains a Strong Buy rating on CVS shares.
News For CVS From the Last 2 Days
CVS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.